Rabeswit‑DSR is designed as a dual therapy capsule combining Rabeprazole 20 mg (enteric‑coated proton pump inhibitor) with Domperidone 30 mg (sustained release prokinetic). This dual‑mode approach delivers prompt acid suppression and improved gastrointestinal motility, ensuring comprehensive management of gastroesophageal reflux disease (GERD), heartburn, bloating, and nausea.
Advantages:
-
Rabeprazole acts at the proton pump level to reduce gastric acid secretion with prolonged relief
-
Domperidone improves gastric emptying, reducing symptoms of fullness, bloating, and nausea
-
Single once-daily dosing enhances patient compliance
Indications:
-
Symptomatic GERD and chronic acidity
-
Gastric and duodenal ulcers
-
Functional dyspepsia, bloating, and indigestion
-
Postprandial discomfort and nausea associated with delayed gastric emptying
Dosage & Administration:
Typically one capsule once daily before breakfast or as directed by a healthcare provider. Swallow without chewing.
Precautions & Contraindications:
-
Avoid concomitant use with certain macrolide antibiotics or antifungals that prolong QT interval
-
Use cautiously in patients with prominence of prolactin-sensitive conditions or heart disease
-
Not recommended in pregnancy and lactation unless prescribed
-
Monitor in patients with liver dysfunction or electrolyte imbalance
Storage:
Store in a sealed container in a cool, dry place away from sunlight and children’s reach.
